Scenario analysis results from the discrete-event simulation model
| Scenario | Country | Incremental costs | Incremental QALYs | ICER |
|---|---|---|---|---|
| Using EMPHASIS-HF data with no extrapolation | UK | £940 | 0.05 | £20 730 |
| Spain | €1427 | 0.05 | €31 138 | |
| Time horizon 2 years | UK | £717 | 0.04 | £20 101 |
| Spain | €1157 | 0.04 | €32 208 | |
| Time horizon 5 years | UK | £1160 | 0.19 | £6016 |
| Spain | €2340 | 0.20 | €11 932 | |
| No utility decrement for adverse events, atrial fibrillation or hospitalisations | UK | £4284 | 1.20 | £3558 |
| Spain | €7358 | 1.32 | €5584 | |
| Increased use of devices | UK | £4495 | 1.22 | £3693 |
| Spain | €7396 | 1.33 | €5560 | |
| No use of devices | UK | £3440 | 1.23 | £2802 |
| Spain | €5223 | 1.34 | €3893 |
EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.